Rachel Pulver
Family · West Linn, ORNPI 1730364563
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,344 of the $3,717 with a category attached, or 63.1%. 16 manufacturers reported payments, led by AbbVie at 30.5% of the total. Reporting peaked in 2021 at $1,630 and has fallen 60.3% since, to $648 in 2025. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $35.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$1K
- Johnson & Johnson$508
- Regeneron Healthcare Solutions, Inc.$220
- Arcutis Biotherapeutics, Inc.$206
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$125
- plus $445 from 10 others
What the payments were for
- Speaking & faculty fees$87524%
- Food & beverage$2,34463%
- Education$49813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $1,132 |
| Sun Pharmaceutical Industries Inc. | 7 | $1,080 |
| Johnson & Johnson | 12 | $508 |
| Regeneron Healthcare Solutions, Inc. | 5 | $220 |
| Arcutis Biotherapeutics, Inc. | 3 | $206 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $125 |
| Lilly USA, LLC | 4 | $89 |
| LEO Pharma Inc. | 4 | $81 |
| UCB, Inc. | 3 | $77 |
| E.r. Squibb & Sons, L.L.C. | 1 | $43 |
| Pfizer | 2 | $36 |
| Sanofi | 2 | $36 |
| Galderma Laboratories, L.p. | 1 | $26 |
| Novartis | 1 | $22 |
| Biofrontera Inc. | 2 | $20 |
| Dermavant Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEVULAN KERASTICK$875
- Cabtreo$125
- Skyrizi$120
How this compares
$3,717 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $164,809 |
| Humira(Cf)Adalimumab | 12 | $78,058 |
| Dupixent PenDupilumab | 12 | $43,221 |
| Ketoconazole | 341 | $7,002 |
| Triamcinolone Acetonide | 344 | $5,113 |
| Econazole Nitrate | 86 | $3,159 |
| Clotrimazole | 157 | $2,001 |
| Clobetasol Propionate | 54 | $1,860 |
| Doxycycline Monohydrate | 79 | $1,774 |
| Betamethasone Dipropionate | 53 | $1,506 |
| Tretinoin | 13 | $873 |
| Metronidazole | 18 | $788 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 33 | $479 |
| Clindamycin Phosphate | 29 | $403 |
| Mupirocin | 26 | $217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $1,132 | $78,05812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in West Linn
- Andrew GerryWest Linn$7K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.